Clinical Trial Update: Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib for recurrent and metastatic triple-negative breast cancer with BRCA1/2 unmutated or BRCA1 promoter methylated status; current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Solid Tumor | Phase 2 | Status: NOT_YET_RECRUITING